Table I.
Patient Characteristics
| Post-Cy All Enrolled Patients | Post-Cy Matched subset | Tacrolimus + MTX Matched Control | * P-value | |
|---|---|---|---|---|
|
| ||||
| N= 49 | N= 37 | N=37 | ||
|
| ||||
| Male/Female | 28/21 | 21/16 | 22/15 | 0.8 |
|
| ||||
| Median Age (range) | 61 years (39–72) | 61 years (39–72) | 62 years (37–72) | 0.8 |
|
| ||||
| Median Co-Morbidity Index (range) | 3 (0–10) | 3 (0–10) | 3 (0–8) | 0.4 |
|
| ||||
| Diagnosis (%) | ||||
| AML/MDS | 40 | 30 (81%) | 30 (81%) | 1.0 |
| ALL | 1 | 1 (3) | 1 (3) | |
| CLL | 5 | 4 (11) | 0 (0) | |
| NHL | 3 | 2 (5) | 6 (16) | |
|
| ||||
| Stage at Transplant (%) | ||||
| CR1 | 9 | 5 | 5 | 1.0 |
| CR2 | 3 | 3 | 4 | |
| Primary Induction Failure | 19 | 12 | 12 | |
| Untreated | 3 | 3 | 4 | |
| >CR2 | 15 | 14 | 12 | |
|
| ||||
| Donor and Stem Cell Source | ||||
| MRD BM | 6 | 6 | 1 | 0.04 |
| MRD PB | 9 | 9 | 14 | |
| MUD BM | 32 | 20 | 16 | 0.1 |
| MUD PB | 2 | 2 | 6 | |
|
| ||||
| ATG (MUD’s only) | 22 | 22 | 22 | 1.0 |
|
| ||||
| RIC Regimen | ||||
| BU/Flu | 49 | 37 | 15 | |
| Flu/Mel | 22 | |||
|
| ||||
| Female D/Male R | 9 | 8 | 3 | 0.09 |
|
| ||||
| CMV Status D/R | ||||
| D + or −/R+ | 39 | 31 | 27 | 0.3 |
| D+/R− | 6 | 3 | 5 | |
| D−/R− | 4 | 3 | 5 | |
*
P value for comparison of Post-Cy matched cohort and Tacrolimus+ MTX matched control